Foundations Investment Advisors LLC Has $2.64 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Foundations Investment Advisors LLC grew its holdings in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 153.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 36,646 shares of the biopharmaceutical company’s stock after buying an additional 22,209 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $2,637,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BMY. Boston Financial Mangement LLC boosted its holdings in Bristol-Myers Squibb by 0.9% in the third quarter. Boston Financial Mangement LLC now owns 15,468 shares of the biopharmaceutical company’s stock valued at $1,100,000 after acquiring an additional 133 shares during the last quarter. Accredited Investors Inc. boosted its holdings in Bristol-Myers Squibb by 0.9% in the third quarter. Accredited Investors Inc. now owns 15,461 shares of the biopharmaceutical company’s stock valued at $1,099,000 after acquiring an additional 134 shares during the last quarter. Lincoln National Corp boosted its holdings in Bristol-Myers Squibb by 0.4% in the third quarter. Lincoln National Corp now owns 36,282 shares of the biopharmaceutical company’s stock valued at $2,579,000 after acquiring an additional 140 shares during the last quarter. CWA Asset Management Group LLC boosted its holdings in Bristol-Myers Squibb by 1.4% in the third quarter. CWA Asset Management Group LLC now owns 10,053 shares of the biopharmaceutical company’s stock valued at $715,000 after acquiring an additional 140 shares during the last quarter. Finally, Elmwood Wealth Management Inc. boosted its holdings in Bristol-Myers Squibb by 1.0% in the third quarter. Elmwood Wealth Management Inc. now owns 13,686 shares of the biopharmaceutical company’s stock valued at $973,000 after acquiring an additional 140 shares during the last quarter. 75.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of several recent research reports. Jefferies Financial Group assumed coverage on Bristol-Myers Squibb in a report on Monday, March 6th. They issued a “hold” rating and a $62.00 price target on the stock. Wells Fargo & Company raised their target price on Bristol-Myers Squibb from $70.00 to $78.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 3rd. StockNews.com assumed coverage on Bristol-Myers Squibb in a report on Thursday. They set a “strong-buy” rating on the stock. Cantor Fitzgerald assumed coverage on Bristol-Myers Squibb in a report on Tuesday, January 17th. They set an “overweight” rating and a $95.00 target price on the stock. Finally, Atlantic Securities raised their target price on Bristol-Myers Squibb from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, February 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Moderate Buy” and a consensus price target of $79.69.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 240,000 shares of the business’s stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the transaction, the chief executive officer now owns 236,104 shares of the company’s stock, valued at approximately $17,625,163.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Bristol-Myers Squibb news, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now owns 23,043 shares of the company’s stock, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Giovanni Caforio sold 240,000 shares of the business’s stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $74.65, for a total value of $17,916,000.00. Following the transaction, the chief executive officer now directly owns 236,104 shares in the company, valued at approximately $17,625,163.60. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Down 0.8 %

Bristol-Myers Squibb stock traded down $0.57 during midday trading on Friday, reaching $66.53. The stock had a trading volume of 21,616,937 shares, compared to its average volume of 8,457,718. The firm’s fifty day simple moving average is $70.96 and its 200-day simple moving average is $72.88. Bristol-Myers Squibb has a 1-year low of $65.28 and a 1-year high of $81.43. The stock has a market capitalization of $139.63 billion, a P/E ratio of 22.55, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.14 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last announced its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.71 by $0.11. Bristol-Myers Squibb had a return on equity of 51.60% and a net margin of 13.71%. The business had revenue of $11.41 billion for the quarter, compared to analyst estimates of $11.20 billion. During the same quarter last year, the firm earned $1.83 EPS. Bristol-Myers Squibb’s revenue for the quarter was down 4.8% compared to the same quarter last year. As a group, analysts expect that Bristol-Myers Squibb will post 8.07 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Investors of record on Monday, April 10th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date is Thursday, April 6th. Bristol-Myers Squibb’s dividend payout ratio is presently 77.29%.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.